ORIGINAL RESEARCH article
Front. Immunol.
Sec. Primary Immunodeficiencies
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1657670
This article is part of the Research TopicDiseases with Immune Dysregulation in AfricaView all 3 articles
Prevalence and Clinical Implications of Major and Minor ANCAs in Tunisian (North African) Patients with Systemic Lupus Erythematosus
Provisionally accepted- 1Faculty of Medicine of Tunis, University of Tunis El Manar, 1068, Tunis, Tunisia
- 2Laboratory of Genetics, Immunology, and Human Pathology, Faculty of Sciences of Tunis, University of Tunis El Manar,, Tunis, Tunisia
- 3Internal medicine department, Mongi Slim University Hospital, Tunis, Tunisia
- 4Clinical immunology department, Pasteur Institute of Tunis, Tunis, Tunisia
- 5Laboratory of Transmission, Control and Immunobiology of Infection, Pasteur Institute of Tunis, 1002, Tunis, Tunisia
- 6Nephrology Department, Mongi Slim University Hospital, Tunis, Tunisia
- 7Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study explores the prevalence, antigenic specificity, and clinical significance of anti-neutrophil cytoplasmic antibodies (ANCAs) in systemic lupus erythematosus (SLE) within a North African (Tunisian) population. While ANCAs have been previously reported in SLE, their relevance remains poorly understood, particularly in African cohorts. Through a case-control study combining indirect immunofluorescence and antigenspecific ELISA, we identify a high prevalence of ANCAs-particularly anti-lactoferrin antibodies-and establish their association with lupus nephritis, cutaneous manifestations, and higher disease activity. Our findings highlight potential ethnic and environmental influences on autoantibody profiles in SLE and suggest that ANCAs, specifically anti-lactoferrin, could serve as biomarkers of disease severity in this population.
Keywords: Ahlem Ben Hmid: Investigation, Writingreview & editing. Cherifa Abdelkéfi: Writingreview & editing. Dhouha Krir: Data curation, Formal analysis, Writingoriginal draft. Hayet Kebaier: Writingreview & editing. Houssem Abida: Data curation, Writing original draft. Imen Zamali: Conceptualization, investigation, supervision, Validation
Received: 01 Jul 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Meddeb, Abida, Krir, Ben Hmid, Aouaidia, Abdelkéfi, Nasri, Sghaier, Kebaier, Samoud, Goucha, B'chir Hamzaoui, Ben Ahmed, Larbi, Zamali and Galai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zeineb Meddeb, Faculty of Medicine of Tunis, University of Tunis El Manar, 1068, Tunis, Tunisia
Imen Zamali, Faculty of Medicine of Tunis, University of Tunis El Manar, 1068, Tunis, Tunisia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.